Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.90 Insider Own27.39% Shs Outstand47.72M Perf Week-13.97%
Market Cap124.58M Forward P/E- EPS next Y-1.83 Insider Trans0.00% Shs Float38.66M Perf Month-2.50%
Income-140.73M PEG- EPS next Q-0.48 Inst Own73.88% Short Float / Ratio5.55% / 5.84 Perf Quarter-19.59%
Sales0.00M P/S- EPS this Y26.74% Inst Trans16.56% Short Interest2.15M Perf Half Y-21.48%
Book/sh2.95 P/B0.79 EPS next Y3.74% ROA-54.49% Target Price9.00 Perf Year-56.99%
Cash/sh3.10 P/C0.75 EPS next 5Y38.60% ROE-67.42% 52W Range1.57 - 7.65 Perf YTD-54.74%
Dividend- P/FCF- EPS past 5Y-39.49% ROI-75.40% 52W High-69.41% Beta0.74
Dividend %- Quick Ratio9.85 Sales past 5Y0.00% Gross Margin- 52W Low49.04% ATR0.22
Employees80 Current Ratio9.85 Sales Q/Q- Oper. Margin0.00% RSI (14)47.70 Volatility9.16% 9.54%
OptionableYes Debt/Eq0.20 EPS Q/Q15.57% Profit Margin- Rel Volume1.08 Prev Close2.49
ShortableYes LT Debt/Eq0.19 EarningsNov 13 BMO Payout- Avg Volume367.20K Price2.34
Recom1.44 SMA20-4.27% SMA506.00% SMA200-33.54% Volume397,517 Change-6.02%
Date Action Analyst Rating Change Price Target Change
Oct-30-23Initiated Wells Fargo Overweight $11
May-26-23Downgrade BofA Securities Buy → Neutral $8 → $3
May-25-23Downgrade JP Morgan Overweight → Neutral $19 → $9
Sep-16-22Initiated Jefferies Buy $12
Sep-09-22Initiated BTIG Research Buy $15
Nov-30-21Initiated H.C. Wainwright Buy $40
Sep-23-21Initiated Cantor Fitzgerald Overweight $40
Jan-26-21Initiated Needham Buy $37
Aug-18-20Initiated JP Morgan Overweight $33
Aug-18-20Initiated Cowen Outperform
Nov-22-23 04:01PM
Nov-14-23 07:20PM
Nov-13-23 06:30AM
Nov-09-23 06:30AM
Oct-24-23 06:30AM
04:01PM Loading…
Oct-18-23 04:01PM
Oct-10-23 06:30AM
Sep-19-23 06:30AM
Sep-18-23 04:01PM
Sep-08-23 09:35AM
Aug-07-23 06:30AM
Aug-02-23 04:01PM
Jul-30-23 12:00PM
Jul-27-23 06:30AM
06:30AM Loading…
Jul-24-23 06:30AM
Jun-14-23 08:36AM
May-30-23 10:40AM
May-26-23 03:05AM
May-25-23 11:52AM
May-24-23 04:01PM
May-16-23 04:01PM
May-08-23 04:01PM
Apr-11-23 06:30AM
Mar-25-23 08:04AM
Mar-06-23 06:30AM
Feb-27-23 06:30AM
Feb-16-23 04:05PM
Feb-12-23 07:35AM
04:30PM Loading…
Jan-17-23 04:30PM
Jan-08-23 09:00AM
Jan-06-23 06:30AM
Jan-04-23 06:30AM
Dec-01-22 09:55AM
Nov-21-22 06:13AM
Nov-17-22 04:01PM
Nov-15-22 09:55AM
Nov-03-22 06:30AM
Oct-18-22 04:01PM
Oct-11-22 07:01AM
Sep-16-22 04:01PM
Sep-01-22 05:56PM
Aug-17-22 04:05PM
Aug-08-22 04:01PM
Jul-11-22 06:25PM
Jul-08-22 07:00AM
Jun-07-22 12:19PM
Jun-02-22 06:30AM
Jun-01-22 07:30AM
May-09-22 04:01PM
May-05-22 06:30AM
Apr-21-22 06:02AM
Apr-18-22 10:35AM
Apr-07-22 06:30AM
Apr-04-22 06:30AM
Mar-03-22 04:01PM
Mar-01-22 04:01PM
Feb-28-22 06:30AM
Jan-20-22 06:30AM
Jan-05-22 05:10PM
Jan-04-22 04:05PM
Dec-31-21 08:30AM
Dec-13-21 09:00AM
Nov-30-21 05:24AM
Nov-28-21 11:17AM
Nov-09-21 04:01PM
Oct-19-21 06:38AM
Oct-04-21 10:49AM
Sep-23-21 06:30AM
Sep-20-21 06:30AM
Sep-16-21 11:30AM
Aug-16-21 04:01PM
Jul-22-21 07:00AM
May-21-21 06:30AM
May-17-21 04:05PM
May-05-21 07:00AM
Apr-22-21 01:47AM
Mar-25-21 07:00AM
Mar-01-21 01:11PM
Feb-08-21 07:00AM
Jan-12-21 07:00AM
Jan-05-21 07:00AM
Dec-21-20 07:00AM
Dec-11-20 01:15PM
Nov-16-20 04:01PM
Nov-12-20 04:05PM
Oct-24-20 10:13AM
Sep-08-20 04:01PM
Jul-30-20 08:00AM
Jul-28-20 04:05PM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bain Capital Life Sciences Inv10% OwnerMay 25Buy2.13300,000639,7205,701,926May 30 09:54 PM
Love DouglasPresident & CEOFeb 15Sale5.876,57138,564197,646Feb 17 05:12 PM
Lew JenniferEVP & Chief Financial OfficerFeb 14Sale6.301661,04629,542Feb 15 06:59 PM
Overdorf MichaelEVP & Chief Business OfficerFeb 14Sale6.3014490727,805Feb 15 07:00 PM
Lew JenniferEVP & Chief Financial OfficerFeb 13Sale6.311,74210,98929,708Feb 15 06:59 PM
Overdorf MichaelEVP & Chief Business OfficerFeb 13Sale6.301,5019,46127,949Feb 15 07:00 PM
Satter Muneer ADirectorFeb 10Buy6.802,647,05817,999,9947,056,024Feb 14 04:31 PM
Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
XLO Xilio Therapeutics Inc daily Stock Chart
Index- P/E- EPS (ttm)-2.96 Insider Own49.72% Shs Outstand27.43M Perf Week-12.24%
Market Cap28.63M Forward P/E- EPS next Y-2.71 Insider Trans0.00% Shs Float13.84M Perf Month-54.89%
Income-81.22M PEG- EPS next Q-0.73 Inst Own25.23% Short Float / Ratio0.21% / 1.28 Perf Quarter-64.14%
Sales0.00M P/S- EPS this Y11.02% Inst Trans-6.70% Short Interest0.03M Perf Half Y-65.10%
Book/sh1.91 P/B0.55 EPS next Y5.50% ROA-69.04% Target Price9.67 Perf Year-57.02%
Cash/sh2.17 P/C0.48 EPS next 5Y- ROE-90.85% 52W Range0.85 - 4.92 Perf YTD-61.34%
Dividend- P/FCF- EPS past 5Y- ROI-133.33% 52W High-78.86% Beta-0.27
Dividend %- Quick Ratio3.81 Sales past 5Y0.00% Gross Margin- 52W Low22.35% ATR0.22
Employees89 Current Ratio3.81 Sales Q/Q- Oper. Margin0.00% RSI (14)31.65 Volatility14.15% 18.92%
OptionableNo Debt/Eq0.27 EPS Q/Q15.76% Profit Margin- Rel Volume0.99 Prev Close0.90
ShortableYes LT Debt/Eq0.16 EarningsNov 09 AMC Payout- Avg Volume22.64K Price1.04
Recom1.25 SMA20-28.79% SMA50-42.32% SMA200-60.76% Volume22,441 Change15.54%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Nov-09-23 04:01PM
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM Loading…
Aug-18-23 04:27AM
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
07:30AM Loading…
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
06:30AM Loading…
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.